Twenty years' experience with post-Chernobyl thyroid cancer.

Best Pract Res Clin Endocrinol Metab

Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, UK.

Published: December 2008

AI Article Synopsis

Article Abstract

Chernobyl, the largest ever nuclear accident, caused a huge release of radioactive isotopes, including nearly 2x10(18) Bq of iodine-131. Four years later an increase in thyroid cancer incidence, virtually all papillary carcinomas in children, occurred in the highly exposed areas. The increase has continued, and with increasing latency the tumour molecular and morphological pathology has changed; further changes may occur in the future. Children under the age of 1 at exposure show the highest susceptibility, and carry this risk with them into adult life; 4000 cases have been attributed to the accident, but so far very few have died. The risk falls rapidly with increasing age at exposure; it is doubtful if there is any risk for adults at exposure. Other factors linked to susceptibility to thyroid carcinogenesis after Chernobyl include dose, iodine deficiency, and genetic factors. Other consequences are briefly covered.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beem.2008.09.020DOI Listing

Publication Analysis

Top Keywords

thyroid cancer
8
age exposure
8
twenty years'
4
years' experience
4
experience post-chernobyl
4
post-chernobyl thyroid
4
cancer chernobyl
4
chernobyl largest
4
largest nuclear
4
nuclear accident
4

Similar Publications

Background: Radioactive iodine (RAI) is a common treatment for various thyroid diseases. Previous studies have suggested susceptibility of parathyroid glands to the mutagenic effect of RAI and the development of primary hyperparathyroidism (PHPT). We tested the possible link between prior RAI treatment, disease presentation, and treatment outcomes.

View Article and Find Full Text PDF

In the primary analysis of the open-label phase III PRECIOUS study, pertuzumab retreatment combined with trastuzumab plus chemotherapy of physician's choice (PTC) significantly improved investigator-assessed progression-free survival (PFS) compared with trastuzumab plus physician's choice chemotherapy (TC) in patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced/metastatic breast cancer (LA/mBC). Here, we report final overall survival (OS) at the median follow-up of 25.8 months.

View Article and Find Full Text PDF

Background: This study aims to establish the characteristics of second primary neoplasms (SPNs) and the long-term follow-up status of a tertiary pediatric oncology center.

Methods: Records of 1799 patients followed up in the pediatric oncology division between January 1981 and December 2022 were evaluated retrospectively.

Results: Thirty-four (1.

View Article and Find Full Text PDF

Background: Bone metastasis is associated with a poor prognosis. Bone-modifying agents (BMA) are commonly used for the prevention or treatment of skeletal-related events (SRE) in patients with bone metastasis; however, whether or not treatment with BMA improves survival remains unclear. In this study, we investigated whether BMA was involved in post-bone metastasis survival.

View Article and Find Full Text PDF

In exploring adjuvant therapies for head and neck cancer, hyperthermia (40-45 °C) has shown efficacy in enhancing chemotherapy and radiation, as well as the delivery of liposomal drugs. Current hyperthermia treatments, however, struggle to reach large deep tumors uniformly and non-invasively. This study investigates the feasibility of delivering targeted uniform hyperthermia deep into the tissue using a non-invasive ultrasound spherical random phased array transducer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!